- Home
- USA vs SPRY Comparison
USA vs SPRY Comparison
Compare USA & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USA
- SPRY
- Stock Information
- Founded
- USA 1986
- SPRY 2015
- Country
- USA United States
- SPRY United States
- Employees
- USA N/A
- SPRY N/A
- Industry
- USA Finance Companies
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- USA Finance
- SPRY Health Care
- Exchange
- USA Nasdaq
- SPRY Nasdaq
- Market Cap
- USA 1.9B
- SPRY 1.8B
- IPO Year
- USA N/A
- SPRY N/A
- Fundamental
- Price
- USA $6.62
- SPRY $14.47
- Analyst Decision
- USA
- SPRY Strong Buy
- Analyst Count
- USA 0
- SPRY 4
- Target Price
- USA N/A
- SPRY $28.75
- AVG Volume (30 Days)
- USA 880.5K
- SPRY 1.5M
- Earning Date
- USA 01-01-0001
- SPRY 08-13-2025
- Dividend Yield
- USA 9.66%
- SPRY N/A
- EPS Growth
- USA N/A
- SPRY N/A
- EPS
- USA N/A
- SPRY N/A
- Revenue
- USA N/A
- SPRY $112,339,000.00
- Revenue This Year
- USA N/A
- SPRY N/A
- Revenue Next Year
- USA N/A
- SPRY $170.64
- P/E Ratio
- USA N/A
- SPRY N/A
- Revenue Growth
- USA N/A
- SPRY 22367.80
- 52 Week Low
- USA $5.62
- SPRY $10.00
- 52 Week High
- USA $7.09
- SPRY $18.90
- Technical
- Relative Strength Index (RSI)
- USA 51.53
- SPRY 29.63
- Support Level
- USA $6.46
- SPRY $15.90
- Resistance Level
- USA $6.65
- SPRY $18.63
- Average True Range (ATR)
- USA 0.07
- SPRY 0.93
- MACD
- USA 0.01
- SPRY -0.38
- Stochastic Oscillator
- USA 78.07
- SPRY 3.59
About USA Liberty All-Star Equity Fund
Liberty All Star Equity Fund is a multi-managed fund. Its objective is to provide a high level of current income and long-term capital appreciation through investing principally in a diversified portfolio of equity securities. The fund invests in various sectors, including financials, information technology, healthcare, consumer discretionary, consumer staples, industrials, energy, materials, real estate, utilities, telecommunication, and other services.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.